Greenland Mines Ltd
Greenland Mines Ltd is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare diseases and Alzheimer’s disease, currently operating at a significant net loss while holding a cash balance of $10.0 million.
Business. Greenland Mines Ltd (GRML) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Greenland Mines Ltd (GRML) has recorded a notable addition to its shareholder base, marking a shift in ownership structure. As of December 31, 2025, investor ID 465 acquired a position of 716,547 shares, valued at approximately $0.21 million. This acquisition represents a weight of roughly 0.0003% in the investor’s portfolio, signaling a new institutional or significant private interest in the company’s equity. This development is particularly relevant given that this is the first analysis for the ticker, meaning there is no prior basis for computing delta changes in shareholder activity. The entry of a new holder into a company with only eight top holders suggests a concentrated ownership environment where individual investor moves can have a disproportionate impact on the shareholder register. The significance of this change is underscored by the company’s current profile, which shows zero analyst coverage and no index membership. In the absence of broad market scrutiny or inclusion in major indices, the addition of a new holder may reflect independent due diligence or a specific strategic interest rather than passive index-driven buying. With no other material changes or cross-source signals detected, this holder addition stands as the primary recent development for GRML. Investors should monitor whether this new position stabilizes or expands, as it could serve as an early indicator of renewed interest in the company’s underlying assets or operational prospects.
Signals & dispatch
Composite-score breakdown
Synthesis
Greenland Mines Ltd (GRML) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
Greenland Mines Ltd maintains a debt-free capital structure with $51.5 million in total equity and $10.0 million in cash and equivalents, resulting in a current ratio of 19.74. The company’s market capitalization of $22.5 million implies a price-to-book ratio of 8.04, reflecting a premium valuation relative to its tangible book value despite negative earnings. Operating cash flow was negative $4.97 million in Q1 2026, driven by a net loss of $13.9 million, which includes non-cash items such as a $2.3 million change in warrant liability fair value and $2.0 million in impairment expenses. The company raised $7.75 million in net proceeds from the sale of securities during the quarter, partially offsetting the cash burn.
Profitability metrics are deeply negative, with a return on equity of -26.9% and return on assets of -23.2%. The company reported an operating loss of $9.5 million in Q1 2026, a significant increase from the $1.6 million operating loss in the same period of 2025. This deterioration was primarily driven by a surge in professional fees to $2.98 million from $0.74 million and general and administrative expenses rising to $6.21 million from $0.85 million year-over-year. Research and development expenses were $0.32 million, indicating early-stage clinical or pre-clinical activity. The net loss per share was $0.15, compared to $0.08 in the prior year period.
Greenland Mines Ltd (GRML) has recorded a notable addition to its shareholder base, marking a shift in ownership structure. As of December 31, 2025, investor ID 465 acquired a position of 716,547 shares, valued at approximately $0.21 million. This acquisition represents a weight of roughly 0.0003% in the investor’s portfolio, signaling a new institutional or significant private interest in the company’s equity. This development is particularly relevant given that this is the first analysis for the ticker, meaning there is no prior basis for computing delta changes in shareholder activity. The entry of a new holder into a company with only eight top holders suggests a concentrated ownership environment where individual investor moves can have a disproportionate impact on the shareholder register. The significance of this change is underscored by the company’s current profile, which shows zero analyst coverage and no index membership. In the absence of broad market scrutiny or inclusion in major indices, the addition of a new holder may reflect independent due diligence or a specific strategic interest rather than passive index-driven buying. With no other material changes or cross-source signals detected, this holder addition stands as the primary recent development for GRML. Investors should monitor whether this new position stabilizes or expands, as it could serve as an early indicator of renewed interest in the company’s underlying assets or operational prospects.
- The company faces substantial doubt about its ability to continue as a going concern without additional funding.
- Operating expenses surged to $9.5 million in Q1 2026, driven by increased professional and administrative costs.
- Significant dilution occurred, with weighted average shares outstanding increasing from 27.5 million to 93.7 million year-over-year.
- The company raised $7.75 million in net proceeds from securities sales, partially offsetting a $4.97 million operating cash outflow.
- A strategic pivot is suggested by the acquisition of mineral rights and exploratory licenses, diverging from its pharmaceutical focus.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Operating income -$9.5M.
- ▍Operating income -$9.5M
Operating income -$5.3M.
- ▍Operating income -$5.3M
Operating income -$3.5M.
- ▍Operating income -$3.5M
Operating income -$7.1M.
- ▍Operating income -$7.1M
Operating income -$5.5M.
- ▍Operating income -$5.5M
Operating income -$5.5M.
- ▍Operating income -$5.5M
Operating income -$1.3M.
- ▍Operating income -$1.3M
Operating income -$631.3k.
- ▍Operating income -$631.3k
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Filings reference going-concern or substantial-doubt language.
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director · Non-Qualified Stock Option → Common StockAcquired 20 000 @ $0,41grant · 2025-12-10
- Director · Non-Qualified Stock Option → Common StockAcquired 20 000 @ $0,41grant · 2025-12-10
- Director · Non-Qualified Stock Option → Common StockAcquired 20 000 @ $0,41grant · 2025-12-10
- Director · Non-Qualified Stock Option → Common StockAcquired 10 000 @ $0,41grant · 2025-08-07
- Director · Non-Qualified Stock Option → Common StockAcquired 10 000 @ $0,41grant · 2025-08-07
- Director · Non-Qualified Stock Option → Common StockAcquired 10 000 @ $0,41grant · 2025-08-07
Actions
Ask Handelsavisen
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Market Capmarket_price * shares_outstanding_diluted
- Return On Assetsnet_income / total_assets
- Price To Tangible Bookmarket_price / (tangible_book_value / shares_outstanding_diluted)
- Enterprise Valuemarket_cap - net_cash
- Cash Conversion Ratiooperating_cash_flow / net_income
- Greenland Mines Ltd company facts · 2026-07-12
- Greenland Mines Ltd 10-Q 2026-05-20 · 2026-07-12
- Greenland Mines Ltd 10-K 2026-04-01 · 2026-07-12
- Greenland Mines Ltd 10-Q 2025-11-13 · 2026-07-12
- Greenland Mines Ltd 10-Q 2025-08-18 · 2026-07-12
- 8-K (sec_8k_material) on GRML · 2026-07-12
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,01 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
- Director · Common StockBought 240 000 @ $0,23$56K · 2026-07-22
- Director · Common StockBought 140 000 @ $0,18$25K · 2026-07-20
- Chief Financial Officer · Common StockBought 1 400 000 @ $0,18$245K · 2026-07-16
- Director · Common StockSold 175 000 @ $0,23$41K · 2026-06-25
- Chief Financial Officer · Common StockOther 2 500 000 · 2026-03-04
- Director · Common StockOther 350 000 · 2026-03-04
- Director · Common StockOther 350 000 · 2026-03-04
- Director · Common StockOther 350 000 · 2026-03-04
- Director · Common StockOther 350 000 · 2026-03-04
- Director, Chief Executive Officer · Common StockOther 2 500 000 · 2026-03-04
- Director, Chief Executive Officer · Common StockOther 400 000 · 2025-09-25
- Chief Financial Officer · Common StockOther 200 000 · 2025-08-25
- Director · Common StockOther 70 149 · 2025-08-05
- Director, Chief Executive Officer · Common StockOther 537 180 · 2025-08-05
- Director · Common StockOther 14 641 · 2025-08-05
- Director · Common StockOther 153 494 · 2025-08-05
- Chief Financial Officer · Common StockOther 156 199 · 2025-08-05
Short positioning
Geographic breakdown
Intel & risk
no material change vs prior analysis (walked 17 fields; 4 schema-expansion field(s) excluded)
- Narrative— → —medium
- Business summary— → —medium
- Conclusion— → —medium
- Key takeaways— → —medium
Evidence & claims
From filings & derived data- Debt-to-equity (FY 2025-12-31): 0.01xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 11,159.0%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 31.2%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 31.2%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -89.8%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 290.4%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 698.4%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -29.0%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -99.9%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -71.6%Derived (calculated)
- Return on equity (FY 2025-12-31): -111.5%Derived (calculated)
- Return on assets (FY 2025-12-31): -110.0%Derived (calculated)
- Current ratio (FY 2025-12-31): 95.01xDerived (calculated)
- Total liabilities (annual): USD 129.76KSEC XBRL filing
- Shareholders' equity (annual): USD 9.46MSEC XBRL filing
- Current assets (annual): USD 7.29MSEC XBRL filing
- Shares outstanding (annual): 72.54MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
- Operating income (annual): USD -7.15MSEC XBRL filing
- R&D expense (annual): USD 634.19KSEC XBRL filing
- Net income (annual): USD -10.55MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
- Operating cash flow (annual): USD -5.89MSEC XBRL filing
- Total assets (annual): USD 9.59MSEC XBRL filing